« Back
Home /
Aldoxorubicin

Aldoxorubicin

Item no.	HY-16261-10mg
Manufacturer	MedChem Express
CASRN	1361644-26-9
Amount	10 mg
Quantity options	100 mg 10 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Breast Cancer Lymphatic System Cancer
Type	Inhibitors
Specific against	other
Purity	95.08
Formula	C37H42N4O13
Dry ice	Yes
Citations	[1]Eric Sanchez, et al. Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206. Clin Cancer Res.2012 18; 3856. [2]Kratz, F. INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies. Current Bioactive Compounds, 2011, 7(1): 33-38(6) [3]Graeser R, et al. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs. 2010 F [4]Walker L, et al. Cell penetrating peptides fused to a thermally targeted biopolymer drug carrier improve the delivery and antitumor efficacy of an acid-sensitive doxorubicin derivative. Int J Pharm. 2012 Oct 15;436(1-2):825-32.
Smiles	[H][C@@]1(O[C@H]2C[C@@](/C(CO)=N/NC(CCCCCN3C(C=CC3=O)=O)=O)(O)CC(C2=C4O)=C(O)C5=C4C(C6=C(OC)C=CC=C6C5=O)=O)O[C@@H](C)[C@@H](O)[C@@H](N)C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	INNO-206; DOXO-EMCH
Shipping Condition	Dry ice
Available
Manufacturer - Type	ADC Related
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	ADC Cytotoxin; Topoisomerase
Shipping Temperature	Dry Ice
Storage Conditions	-80°C, stored under nitrogen
Molecular Weight	750.75
Product Description	Aldoxorubicin (INNO-206) is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
Manufacturer - Research Area	Cancer
Solubility	DMSO : ≥ 50 mg/mL
Manufacturer - Pathway	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Isoform	Daunorubicins/Doxorubicins; Topo II
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-16261-10mg-safety-datasheet.pdf